✦ LIBER ✦

P965 PERSONALIZED THERAPY WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA

✍ Scribed by Cabibbo, G.; Iavarone, M.; Maida, M.; Di Martino, A.; Orlando, E.; Zavaglia, C.; Grieco, A.; Villa, E.; Piscaglia, F.; Di Marco, V.; Colombo, M.; Craxì, A.; Cammà, C.

Book ID: 122167077
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 55 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)61125-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Personalized sorafenib therapy for hepat

Personalized sorafenib therapy for hepatocellular carcinoma

✍ Cabibbo, G.; Iavarone, M.; Maida, M.; di Martino, A.; Orlando, E.; Zavaglia, C.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Sorafenib in Advanced Hepatocellular Car

Sorafenib in Advanced Hepatocellular Carcinoma: A Further Step Toward Personalized Therapy of Liver Cancer

✍ Massimo Colombo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Sorafenib and Triptolide as Combination

Sorafenib and Triptolide as Combination Therapy for Hepatocellular Carcinoma

✍ Alsaied, O.; Sangwan, V.; Banerjee, S.; Chugh, R.; Saluja, A.; Vickers, S.; Jens 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Hepatocellular carcinoma treated with so

Hepatocellular carcinoma treated with sorafenib

✍ G. Han; Y. Zhao; X. Qi; D. Fan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Sequential therapy with sunitinib and so

Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma

✍ Hee Kyung Ahn, Soohyeon Lee, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 134 KB

Sorafenib therapy in patients with hepat

Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation

✍ Ian A. Rowe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB 👁 1 views

The team of Liu et al. generated endoderm-derived human induced pluripotent stem (iPS) cells from primary hepatocytes. 1 However, they generated human iPS cells by using viral transgenes. 1 Clinical applications of human iPS cells require avoiding viral transgenes. On the other hand, the reprogrammi